A biotech company engaged an established, full-service CRO to launch a high-profile peptide drug discovery program. The CRO completed a phage display screen with a single peptide library and reported candidate binding sequences. However, when the peptides were resynthesized off phage, the binding activity failed to reproduce, halting progress and leaving the biotech several months behind schedule. Learn how Tango Biosciences successfully enabled an entire platform and several programs previously stalled allowing the biotech to meet its original milestone and re-establish confidence in its platform.
Subscribe to our email newsletter to access this Case Study
We promise not to spam you, only share relevant updates about Tango Biosciences.
"*" indicates required fields
